• Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3154885 [ Time Frame: Predose up to 96 hours postdose ]
  PK: Cmax of LY3154885
• PK: Time to Cmax (Tmax) of LY3154885 [ Time Frame: Predose up to 96 hours postdose ]
  PK: Tmax of LY3154885
• PK: Area Under the Concentration Versus Time Curve (AUC) of LY3154885 [ Time Frame: Predose up to 96 hours postdose ]
  PK: AUC of LY3154885

• Drug: LY3154885 - Capsule
  Administered orally.
• Drug: Placebo - Capsule
  Administered orally.
• Drug: Itraconazole
  Administered orally.
• Drug: LY3154885 - Tablet
  Administered orally.

• Experimental: LY3154885 - Part A
  LY3154885 administered orally in two of three study periods.
  Intervention: Drug: LY3154885 - Capsule
• Placebo Comparator: Placebo - Part A
  Placebo administered orally in one of three study periods.
  Intervention: Drug: Placebo - Capsule
• Experimental: LY3154885 - Part B
  LY3154885 administered orally alone.
  Intervention: Drug: LY3154885 - Capsule
• Placebo Comparator: Placebo - Part B
  Placebo administered orally alone.
  Intervention: Drug: Placebo - Capsule
• Experimental: LY3154885 + Itraconazole - Part B
  LY3154885 administered alone, orally, once. Itraconazole administered alone, orally, on consecutive days. LY3154885 co-administered with itraconazole, orally, once.
  Interventions:

  • Drug: LY3154885 - Capsule
  • Drug: Itraconazole
• Placebo Comparator: Placebo + Itraconazole - Part B
  Placebo administered alone, orally, once. Itraconazole administered alone, orally, on consecutive days. Placebo co-administered with itraconazole, orally, once.
  Interventions:

  • Drug: Placebo - Capsule
  • Drug: Itraconazole
• Experimental: LY3154885 - Part C
  LY3154885 administered orally on consecutive days.
  Intervention: Drug: LY3154885 - Capsule
• Placebo Comparator: Placebo - Part C
  Placebo administered orally on consecutive days.
  Intervention: Drug: Placebo - Capsule
• Experimental: LY3154885 - Part D
  LY3154885 administered orally once in each of three study periods.
  Interventions:

  • Drug: LY3154885 - Capsule
  • Drug: LY3154885 - Tablet

Inclusion Criteria:

• Are overtly healthy males or females, as determined by medical history and physical examination

• Male participants:

  • Men, regardless of their fertility status, with partners who are nonpregnant women of childbearing potential, must agree to either remain abstinent (if this is their preferred and usual lifestyle) or use condoms with spermicide as well as 1 additional highly effective (<1% failure rate) method of contraception or effective method of contraception (such as diaphragms with spermicide) for 3 months following dosing
  • Men with pregnant partners should use condoms with spermicide during intercourse for the duration of the study or for 3 months following dosing, whichever is longer
  • Men who are in exclusively same-sex relationships (as their preferred and usual lifestyle) or with female partners of nonchildbearing potential are not required to use contraception
  • Men should refrain from sperm donation for the duration of the study or for 3 months following the last dose of study drug, whichever is longer

• Female participants of nonchildbearing potential, including those who are:

  • Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, confirmed tubal ligation, or tubal occlusion) or congenital anomaly such as Müllerian agenesis; or

  • Postmenopausal, defined as 1 of the following:

    • A woman at least 50 years of age with an intact uterus, not on hormone replacement therapy, who has had either:

      • Cessation of menses for at least 1 year; or
      • At least 6 months of spontaneous amenorrhea with a follicle-stimulating hormone level ≥40 milli-international units per milliliter (mIU/mL) at screening
    • A woman at least 55 years of age, not on hormone replacement therapy, who has had at least 6 months of spontaneous amenorrhea; or
    • A woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy
• Have a body mass index (BMI) of 18.0 to 35.0 kilograms per square meter (kg/m²), inclusive

Exclusion Criteria:

• Have a marked baseline prolongation of/corrected QT (QTc) interval (for example, repeated demonstration of a QTcB interval >450 milliseconds [msec] for males or >470 msec for females);

  • A history of additional risk factors for Torsades de Pointes (for example, heart failure, hypokalemia, family history of Long QT Syndrome);
  • The use of concomitant medications that prolong the QT/QTc interval
• Have an abnormal blood pressure (BP) (taken after the participant has been in a supine position for at least 5 minutes) for the population, as determined by a systolic BP >140 millimeters of mercury (mmHg) or a diastolic BP >90 mmHg at screening or a preexisting history of hypertension. Up to 2 additional measurements may be taken after an appropriate resting interval at screening to confirm eligibility
• Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (such as Cushing syndrome, hyperthyroidism, hyperaldosteronism), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational medicinal product (IMP); or of interfering with the interpretation of data
• Have a history of or current significant psychiatric disorders